Risk of recurrence and bleeding in patients with cancer ‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
ConclusionIn this clinical practice setting, rivaroxaban was rarely used for cancer ‐associated VTE. However, among those who received rivaroxaban, the treatment appeared safe and effective with rates comparable to previous studies of selected populations.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Mette S øgaard,
Peter Brønnum Nielsen,
Flemming Skjøth,
Jette Nordstrøm Kjældgaard,
Torben Bjerregaard Larsen Tags: ORIGINAL RESEARCH Source Type: research
More News: Bleeding | Breast Cancer | Cancer | Cancer & Oncology | Denmark Health | Gastroenterology | Hematology | Lung Cancer | Pulmonary Thromboembolism | Study | Thrombosis